Found: 12
Select item for more details and to access through your institution.
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 101, doi. 10.2147/LCTT.S433195
- By:
- Publication type:
- Article
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 85, doi. 10.2147/LCTT.S430967
- By:
- Publication type:
- Article
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 79, doi. 10.2147/LCTT.S431252
- By:
- Publication type:
- Article
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 71, doi. 10.2147/LCTT.S419395
- By:
- Publication type:
- Article
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 57, doi. 10.2147/LCTT.S413091
- By:
- Publication type:
- Article
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 63, doi. 10.2147/LCTT.S413611
- By:
- Publication type:
- Article
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 11, doi. 10.2147/LCTT.S388047
- By:
- Publication type:
- Article
CodeBreak 200: Sotorasib Has Not Broken the KRAS<sup>G12C</sup> Enigma Code.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 27, doi. 10.2147/LCTT.S403461
- By:
- Publication type:
- Article
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 31, doi. 10.2147/LCTT.S403614
- By:
- Publication type:
- Article
Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 47, doi. 10.2147/LCTT.S386344
- By:
- Publication type:
- Article
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 1, doi. 10.2147/LCTT.S379389
- By:
- Publication type:
- Article
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 41, doi. 10.2147/LCTT.S408886
- By:
- Publication type:
- Article